| Literature DB >> 35829933 |
Jacob Ghotbi1, Mushegh Sahakyan2, Kjetil Søreide3,4, Åsmund Avdem Fretland1,2, Bård Røsok1, Tore Tholfsen1, Anne Waage1, Bjørn Edwin2,5, Knut Jørgen Labori1,5, Sheraz Yaqub1,5, Dyre Kleive6.
Abstract
Minimally invasive pancreatoduodenectomy has gained popularity throughout the last decade. For laparoscopic pancreatoduodenectomy, some high-level evidence exists, but with conflicting results. There are currently no published randomized controlled trials comparing robotic and open pancreatoduodenectomy. Comparative long-term data for patients with pancreatic ductal adenocarcinoma is lacking to date. Based on the existing evidence, current observed benefits of minimally invasive pancreatoduodenectomy over open pancreatoduodenectomy seem scarce, but retrospective data indicate the safety of these procedures in selected patients. As familiarity with the robotic platform increases, studies have shown an expansion in indications, also including patients with vascular involvement and even indicating favorable results in patients with obesity and high-risk morphometric features. Several ongoing randomized controlled trials aim to investigate potential differences in short- and long-term outcomes between minimally invasive and open pancreatoduodenectomy. Their results are much awaited.Entities:
Keywords: Adenocarcinoma; Laparoscopic; Minimally invasive surgery; Pancreatoduodenectomy
Year: 2022 PMID: 35829933 DOI: 10.1007/s40487-022-00203-6
Source DB: PubMed Journal: Oncol Ther ISSN: 2366-1089